Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $15 price target.
Baird Maintains Neutral on Sage Therapeutics, Maintains $15 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.